Tenaya Therapeutics, Inc.
TNYAHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Tenaya Therapeutics, Inc. (TNYA) is listed under Biotechnology. The company carries a $153.2M market cap, placing it firmly in the micro-cap category. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Market Cap
$153.2M
Beta
2.78
P/E (TTM)
—
P/E (Fwd)
-1.74
EPS (TTM)
$-0.51
EPS (Fwd)
$-0.39
ROE
-121.9%
ROA
-47.9%
Cash
$78.1M
Total Debt
$3.9M
Free CF
-$32.6M
52W Change
-47.5%
Annual Financials
Cash vs Debt
Where TNYA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TNYA finished 6.67% below its 150-day moving average ($0.75) and 12.50% below its 200-day moving average ($0.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TNYA overbought or oversold?
At the September 3, 2026 close, TNYA's RSI(14) was 39.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $78.1M in cash comfortably exceeding the $3.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$32.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -121.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 2.78 means TNYA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Tenaya Therapeutics, Inc.'s trajectory.